Compare CGEN & MSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGEN | MSD |
|---|---|---|
| Founded | 1993 | 1993 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.2M | 151.1M |
| IPO Year | 2001 | N/A |
| Metric | CGEN | MSD |
|---|---|---|
| Price | $2.20 | $7.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 216.3K | 108.0K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.26% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $112.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.13 | $6.91 |
| 52 Week High | $2.38 | $7.94 |
| Indicator | CGEN | MSD |
|---|---|---|
| Relative Strength Index (RSI) | 57.76 | 29.67 |
| Support Level | $1.47 | N/A |
| Resistance Level | $2.35 | $7.47 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 61.35 | 12.86 |
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.